UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED 30TH SEPTEMBER, 2004
(RS. IN LACS)
PARTICULARS
3 months
3 months
6 months
6 months
Year
30.09.2004
30.09.2003
30.09.2004
30.09.2003
31.03.2004
Unaudited
Unaudited
Unaudited
Unaudited
Audited
Net Sales/Operational Income
4548.05
3859.88
8948.05
7678.98
16652.16
Others Income
8.07
7.36
32.44
34.35
193.11
TOTAL EXPENDITURE :
3439.34
3297.19
7203.87
6722.95
14688.67
(a) (Increase)/decrease in stock in trade
-552.27
-150.55
-880.91
-183.65
-675.87
(b) Consumption of Raw Material
3014.39
2754.15
6088.62
5575.11
12256.41
(c) Staff Cost
88.36
57.17
178.29
108.92
245.21
(d) Other expenditure
888.86
636.42
1817.85
1222.56
2862.92
Interest
160.61
191.39
363.43
379.94
708.31
Depreciation
93.28
63.54
182.98
124.27
278.67
Profit(+)/Loss(-) before tax
862.88
315.13
1230.21
486.17
1169.62
Provision for taxation
67.66
23.31
96.46
34.75
75.48
Net Profit/Loss before Deferred Tax
795.22
291.82
1133.75
451.42
1094.14
Provision for deferred tax
92.92
76.22
145.50
97.42
324.98
Net Profit/Loss
702.30
215.60
988.25
354.00
769.17
Paid up Equity Share Capital
1561.37
1438.63
1561.37
Reserve excluding revaluation reserves
4570.00
3106.68
3581.75
EPS Rs. Basic
4.50
1.57
6.33
2.58
5.24
Diluted
4.50
1.57
6.33
2.58
4.87
Aggregated on Non-Promoters Shareholding
No. of Shares
9779594
8464289
9779594
% of Shareholding
62.63%
58.84%
62.63%
Notes:
a) The company has been steadily building a
platform for a foray into regulated Markets. It has committed significant resources
to create global level capacities with FDA approved facilities for its high potential
drugs clarithromycin, fexofenadine and atorvastatin. The first USFDA approval is
expected by this year-end or early next year after which the company?s sales to
US will commence significantly. The company?s foray into regulated market is expected
to contribute significantly to both top-line and bottom-line.
b) The company has focused on CRAMS in a big
way. It is expanding capacities, putting up new facilities and setting up separate
R&D center to focus on this highly remunerative business segment. The company
has tied-up with two European companies for the contract research for development
of non-infringing processes for a hypertensive drug and a cardiovascular drug. The
company also has sizeable order CRAMS order in pipeline from global generic and
innovator companies to be executed over a period of 2-3 years.
c) The company?s strong R&D efforts have
led to successful commercialization of 18 products so far, while around 20 new products
are in pipeline to be launched over next two to three years. The company has already
filed its first DMF in the US, while two DMFs have been filed in Europe. Going forward,
the company expects to file around four to six DMFs every year in US.
d)There was one complaint pending at the beginning
of the quarter, 5 complaints were received during the quarter, which were duly redressed
to the satisfaction of shareholders. There was no complaint pending as on 30th September,
2004.
e) The previous period figures have been re-grouped
and re-arranged wherever necessary.
f) The above results were taken on record by
the Board of Directors in its meeting held on 26th October, 2004
For Ind-Swift Laboratories Limited
Sd/-
Sd/-
Place:Chandigarh
(N.R.MUNJAL)
(V.K.MEHTA)
Date:26.10.2004
Managing Director
Jt.Managing Director
To know about our Formulation Division, please visit us at Ind-Swift Limited, our other
group company.
